Zealand Pharma executed transactions to repurchase 205,000 shares during week 29 (July 13-17, 2026) as part of its ongoing share buy-back program authorized for up to DKK 1.3 billion. The total shares repurchased under the program now amount to 1,994,000, with Zealand Pharma holding about 4% of its share capital as treasury shares. This buy-back program, managed independently by Danske Bank, aims to support shareholder value and will continue until October 31, 2026.
The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...
FTX is set to distribute an additional $900 million to creditors, bringing total repayments to over $10 billion. This milestone marks significant progress in the bankruptcy process, offering hope to creditors who have been awaiting recovery of their ...
Zoom Communications has appointed Carlos Quaderi as Head of Asia Pacific (APAC), effective August 1, 2026, to lead its growth strategy across the region excluding Japan. Quaderi, with over 30 years of experience and previous leadership roles at Workd...
Nexa Resources is transforming from a zinc-focused producer to a diversified metals miner, with silver, copper, lead, and gold increasingly contributing to its earnings. Recent EBITDA improvements are largely due to high by-product metal prices, rais...
Bitcoin options market data reveals a bullish shift as call options dominate 65.27% of open interest, signaling strong trader confidence in price gains. Open interest rose to nearly $32 billion with $3 billion in daily volume, indicating active parti...
